Real life data often highlight side effects of certain drugs not previously reported in randomized controlled trials (RCTs). Objective. To describe cutaneous inflammatory eruptions in psoriatic patients treated with an anti IL-17A agent (secukinumab or ixekizumab). Methods. Retrospective analysis of a cohort of patients with chronic plaque psoriasis who started an anti IL17A agent between September 2016-February 2019 and who developed cutaneous inflammatory eruptions during treatment. A systematic review of similar events reported in the literature was performed. Results. Data of 468 patients were reviewed and 27 cutaneous inflammatory eruptions of 27 patients were collected (prevalence 5.8%). The eruptions appeared after a mean of 16.9
Biologic agents perception in patients attending for the first-time to psoriasis centers. A multicenter Italian survey / Luca, M; Musumeci, Ml; Bardazzi, F; Potenza, C; Bernardini, N; Ferrara, F; Pavone, A; Micali, G.. - In: GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA. - ISSN 1827-1820. - 155:2(2020), pp. 150-154. [10.23736/S0392-0488.17.05754-6]
Biologic agents perception in patients attending for the first-time to psoriasis centers. A multicenter Italian survey
Potenza C;Bernardini N;
2020
Abstract
Real life data often highlight side effects of certain drugs not previously reported in randomized controlled trials (RCTs). Objective. To describe cutaneous inflammatory eruptions in psoriatic patients treated with an anti IL-17A agent (secukinumab or ixekizumab). Methods. Retrospective analysis of a cohort of patients with chronic plaque psoriasis who started an anti IL17A agent between September 2016-February 2019 and who developed cutaneous inflammatory eruptions during treatment. A systematic review of similar events reported in the literature was performed. Results. Data of 468 patients were reviewed and 27 cutaneous inflammatory eruptions of 27 patients were collected (prevalence 5.8%). The eruptions appeared after a mean of 16.9| File | Dimensione | Formato | |
|---|---|---|---|
|
Luca_Biologic-agents_2020.pdf
accesso aperto
Note: https://www.minervamedica.it/it/riviste/Ital-J-Dermatol-Venereol/articolo.php?cod=R23Y2020N02A0150#
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
324.19 kB
Formato
Adobe PDF
|
324.19 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
